Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma

Liver Transplantation

Volumn 22, Issue 10, 2016, Pages 1356-1366

  Young, Kellie ^a,c   Aguilar, Maria ^b   Gish, Robert ^d   Younossi, Zobair ^e,f   Saab, Sammy ^g   Bhuket, Taft ^b   Liu, Benny ^b   Ahmed, Aijaz ^d   Wong, Robert J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HIGHLAND HOSPITAL   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Center for Liver Diseases   (United States)

^f BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASIAN; CAUCASIAN; COHORT ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS C; HISPANIC; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

EID: 84990868174     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24507     Document Type: Article

References (35)

1. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.; for United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
2. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003;9:12-18.
3. Biggins SW, Bambha K. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006;26:211-220.
4. Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, et al. Model for End-Stage Liver Disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006;12(suppl 3):S128-S136.
5. UNOS/OPTN. Policy 9.3.D specific MELD/PELD exceptions. Policy 9.3.G candidates with hepatocellular carcinoma (HCC). http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf#nameddest=Policy_09. Accessed June 12, 2015.
6. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004;127(suppl 1):S261-S267.
7. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10:1643-1648.
8. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-1351.
9. Wong RJ, Devaki P, Nguyen L, Cheung R, Cho-Phan C, Nguyen MH. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-Stage Liver Disease score. Clin Gastroenterol Hepatol 2014;12:1534-1540.
10. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010;10(part 2):1003-1019.
11. Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015;61:285-291.
12. Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015;61:285-291.
13. Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in waitlist mortality rates with increased Model for End-Stage Liver Disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012;18:434-443.
14. Gish RG, Wong RJ, Honerkamp-Smith G, Xu R, Osorio RW. United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board. Clin Transplant 2015;29:513-522.
15. Roberts JP, Dykstra DM, Goodrich NP, Rush SH, Merion RM, Port FK. Geographic differences in event rates by Model for End-Stage Liver Disease score. Am J Transplant 2006;6:2470-2475.
16. Yeh H, Smoot E, Schoenfeld DA, Markmann JF. Geographic inequity in access to livers for transplantation. Transplantation 2011;91:479-486.
17. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188-2195.
18. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-555.
19. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-497.
20. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-1529.
21. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
22. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-1253.
23. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058.
24. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006;12:523-534.
25. O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011;9:700-704.
26. Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC cancer 2015;15:210.
27. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
28. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-612.
29. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, Humar A, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-1819.
30. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-254.
31. Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, et al. Delayed hepatocellular carcinoma Model for End-Stage Liver Disease exception score improves disparity in access to liver transplant in the United States. Hepatology 2015;61:1643-1650.
32. Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, et al.; for Liver Transplantation North Italy Transplant program (NITp) working group. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014;60:290-297.
33. Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006;6:1957-1962.
34. Goldberg DS, Olthoff KM. Standardizing MELD exceptions: current challenges and future directions. Curr Transplant Rep 2014;1:232-237.
35. Washburn K. Model for End-Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant Rev (Orlando) 2010;24:11-17.